GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Transcenta Holding Ltd (HKSE:06628) » Definitions » Earnings Yield (Joel Greenblatt) %

Transcenta Holding (HKSE:06628) Earnings Yield (Joel Greenblatt) % : -34.60% (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Transcenta Holding Earnings Yield (Joel Greenblatt) %?

Transcenta Holding's Enterprise Value for the quarter that ended in Dec. 2023 was HK$1,413.19 Mil. Transcenta Holding's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-488.70 Mil. Transcenta Holding's Earnings Yield (Joel Greenblatt) for the quarter that ended in Dec. 2023 was -34.60%.

The historical rank and industry rank for Transcenta Holding's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:

HKSE:06628' s Earnings Yield (Joel Greenblatt) % Range Over the Past 10 Years
Min: -15667.29   Med: -35.93   Max: 9642.41
Current: -77.52

During the past 5 years, the highest Earnings Yield (Joel Greenblatt) of Transcenta Holding was 9642.41%. The lowest was -15667.29%. And the median was -35.93%.

HKSE:06628's Earnings Yield (Joel Greenblatt) % is ranked worse than
81.29% of 1411 companies
in the Biotechnology industry
Industry Median: -15.93 vs HKSE:06628: -77.52

Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.

A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. Transcenta Holding's Forward Rate of Return (Yacktman) % for the quarter that ended in Dec. 2023 was 0.00%. The Forward Rate of Return uses the normalized Free Cash Flow of the past seven years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.


Transcenta Holding Earnings Yield (Joel Greenblatt) % Historical Data

The historical data trend for Transcenta Holding's Earnings Yield (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Transcenta Holding Earnings Yield (Joel Greenblatt) % Chart

Transcenta Holding Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Earnings Yield (Joel Greenblatt) %
- - -67.11 -57.14 -34.60

Transcenta Holding Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Earnings Yield (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only -67.11 - -57.14 - -34.60

Competitive Comparison of Transcenta Holding's Earnings Yield (Joel Greenblatt) %

For the Biotechnology subindustry, Transcenta Holding's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Transcenta Holding's Earnings Yield (Joel Greenblatt) % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Transcenta Holding's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Transcenta Holding's Earnings Yield (Joel Greenblatt) % falls into.



Transcenta Holding Earnings Yield (Joel Greenblatt) % Calculation

In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.

Transcenta Holdings Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Dec. 2023 is calculated as

Earnings Yield (Joel Greenblatt)=EBIT/Enterprise Value
=-488.704/1413.18777
=-34.58 %

For company reported semi-annually or annually, GuruFocus only calculate annual data for Earnings Yield (Joel Greenblatt) and apply the annual figure to corresponding quarter.



Transcenta Holding  (HKSE:06628) Earnings Yield (Joel Greenblatt) % Explanation

Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.

Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.


Be Aware

Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.

Forward Rate of Return (Yacktman) % based on Don Yacktman's definition is a better measure of the expected rate of return for a stock.


Transcenta Holding Earnings Yield (Joel Greenblatt) % Related Terms

Thank you for viewing the detailed overview of Transcenta Holding's Earnings Yield (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.


Transcenta Holding (HKSE:06628) Business Description

Industry
Traded in Other Exchanges
N/A
Address
B6-501, 218 Xinghu Street, Biobay, Suzhou, CHN, 215123
Transcenta Holding Ltd is a clinical stage biopharmaceutical company with fully integrated capacities in discovery, research, development and manufacturing. It is developing nine therapeutic antibody molecules for oncology and selected non-oncology indications including bone and kidney disorders. Geographically the company operates in China (the "PRC") and the USA.
Executives
Qian Xueming 2101 Beneficial owner
Shi Xiaohong 2501 Other
Lav Corporate Gp, Ltd. 2201 Interest of corporation controlled by you
Lav Gp Iii, L.p. 2201 Interest of corporation controlled by you
Lav Biosciences Fund Iii, L.p. 2101 Beneficial owner
Shi Yi 2201 Interest of corporation controlled by you
Lav Asset Management (hong Kong) Limited 2102 Investment manager
Fullerton Management Pte Ltd
Temasek Life Sciences Private Limited
Tls Beta Pte. Ltd.
Hsbc Trust Company (delaware), N.a. 2301 Trustee
Success Link International L.p. 2101 Beneficial owner
Temasek Holdings (private) Limited
Lav Vitality Limited 2101 Beneficial owner
Zhong Guo Guo You Qi Ye Jie Gou Tiao Zheng Ji Jin Gu Fen You Xian Gong Si 2501 Other

Transcenta Holding (HKSE:06628) Headlines

No Headlines